Inhibition of DYRK1A stimulates human β-cell proliferation

Diabetes

Volumn 65, Issue 6, 2016, Pages 1660-1671

  Dirice, Ercument ^a   Walpita, Deepika ^b   Vetere, Amedeo ^b   Meier, Bennett C ^b   Kahraman, Sevim ^a   Hu, Jiang ^a   Dančík, Vlado ^b   Burns, Sean M ^c,d   Gilbert, Tamara J ^b   Olson, David E ^b   Clemons, Paul A ^b   Kulkarni, Rohit N ^a   Wagner, Bridget K ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODOTUBERCIDIN; ADENOSINE KINASE; HARMINE; PHOSPHOTRANSFERASE; PROTEIN DYRK1A; PROTEIN P27; SHORT HAIRPIN RNA; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; 5-IODOTUBERCIDIN; DYRK KINASE; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; TUBERCIDIN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; KIDNEY CAPSULE; KIDNEY PARENCHYMA; LIVER; MALE; MOUSE; MUSCLE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PHOSPHORYLATION;

ANIMALS; CELL PROLIFERATION; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; HUMANS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED NOD; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TUBERCIDIN;

EID: 84969849459     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1127     Document Type: Article

References (50)

1. Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov 2014;13:278-289
2. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004;429:41-46
3. Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocaña A. Human β-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes 2014;63:819-831
4. Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF. Human β-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes 2012;61:2205-2213
5. Annes JP, Ryu JH, Lam K, et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc Natl Acad Sci U S A 2012;109:3915-3920
6. Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009;106:15768-15773
7. Vetere A, Wagner BK. Chemical methods to induce beta-cell proliferation. Int J Endocrinol 2012;2012:925143
8. Dirice E, Kahraman S, Jiang W, et al. Soluble factors secreted by T cells promote β-cell proliferation. Diabetes 2014;63:188-202
9. El Ouaamari A, Kawamori D, Dirice E, et al. Liver-derived systemic factors drive β cell hyperplasia in insulin-resistant states. Cell Reports 2013;3:401-410
10. El Ouaamari A, Dirice E, Gedeon N, et al. SerpinB1 promotes pancreatic beta cell proliferation. Cell Metab 2016;23:194-205
11. Dirice E, Kulkarni RN. Harnessing immune cells to enhance β-cell mass in type 1 diabetes. J Investig Med 2016;64:14-20
12. Georgia S, Hinault C, Kawamori D, et al. Cyclin D2 is essential for the compensatory beta-cell hyperplastic response to insulin resistance in rodents. Diabetes 2010;59:987-996
13. Zhou JX, Dhawan S, Fu H, et al. Combined modulation of polycomb and trithorax genes rejuvenates β cell replication. J Clin Invest 2013;123:4849-4858
14. Gregg BE, Moore PC, Demozay D, et al. Formation of a human β-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012;97:3197-3206
15. Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008;57:1584-1594
16. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
17. Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187-191
18. Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC. Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev 2014;30:154-162
19. Walpita D, Hasaka T, Spoonamore J, et al. A human islet cell culture system for high-throughput screening. J Biomol Screen 2012;17:509-518
20. Walpita D, Wagner BK. Evaluation of compounds in primary human islet cell culture. Curr Protoc Chem Biol 2014;6:157-168
21. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A 2008;105:2415-2420
22. Fiaschi-Taesch N, Bigatel TA, Sicari B, et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. Diabetes 2009;58:882-893
23. Fiaschi-Taesch NM, Salim F, Kleinberger J, et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 2010;59:1926-1936
24. Shen W, Taylor B, Jin Q, et al. Inhibition of DYRK1A and GSK3B induces human β-cell proliferation. Nat Commun 2015;6:8372
25. Wang P, Alvarez-Perez JC, Felsenfeld DP, et al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med 2015;21:383-388
26. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P. Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells. Endocrinology 2004;145:667-678
27. Dorrell C, Schug J, Lin CF, et al. Transcriptomes of the major human pancreatic cell types. Diabetologia 2011;54:2832-2844
28. Diiorio P, Jurczyk A, Yang C, et al. Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2rγnull Ins2Akita mice. Pancreas 2011;40:1147-1149
29. Levitt HE, Cyphert TJ, Pascoe JL, et al. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia 2011;54:572-582
30. Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci U S A 2001;98:7475-7480
31. Wang W, Walker JR, Wang X, et al. Identification of small-molecule inducers of pancreatic beta-cell expansion. Proc Natl Acad Sci U S A 2009;106:1427-1432
32. Shen W, Tremblay MS, Deshmukh VA, et al. Small-molecule inducer of β cell proliferation identified by high-throughput screening. J Am Chem Soc 2013;135:1669-1672
33. Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, et al. Expansion and redifferentiation of adult human pancreatic islet cells. Biochem Biophys Res Commun 2006;341:291-298
34. Russ HA, Bar Y, Ravassard P, Efrat S. In vitro proliferation of cells derived from adult human beta-cells revealed by cell-lineage tracing. Diabetes 2008;57:1575-1583
35. Jarvis MF, Yu H, Kohlhaas K, et al. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl) pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J Pharmacol Exp Ther 2000;295:1156-1164
36. Zheng GZ, Lee C, Pratt JK, et al. Pyridopyrimidine analogues as novel adenosine kinase inhibitors. Bioorg Med Chem Lett 2001;11:2071-2074
37. Gao Y, Davies SP, Augustin M, et al. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J 2013;451:313-328
38. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315
39. Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W. The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 2014;13:2084-2100
40. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550
41. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 2007;23:3251-3253
42. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011;25:801-813
43. Mercer SE, Friedman E. Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival. Cell Biochem Biophys 2006;45:303-315
44. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006;441:595-600
45. Goodyer WR, Gu X, Liu Y, Bottino R, Crabtree GR, Kim SK. Neonatal β cell development in mice and humans is regulated by calcineurin/NFAT. Dev Cell 2012;23:21-34
46. Rachdi L, Kariyawasam D, Aïello V, et al. Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance. Cell Cycle 2014;13:2221-2229
47. Rachdi L, Kariyawasam D, Guez F, et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia 2014;57:960-969
48. Knight ZA, Shokat KM. Chemical genetics: where genetics and pharmacology meet. Cell 2007;128:425-430
49. Rosenthal AS, Tanega C, Shen M, et al. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett 2011;21:3152-3158
50. Coombs TC, Tanega C, Shen M, et al. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett 2013;23:3654-3661